{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:37:29Z","timestamp":1791862649989,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54HD082008"],"award-info":[{"award-number":["U54HD082008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54HD104461"],"award-info":[{"award-number":["U54HD104461"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-72935-6","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T06:02:36Z","timestamp":1727935356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership in Fragile X Syndrome"],"prefix":"10.1038","volume":"14","author":[{"given":"Lauren E.","family":"Ethridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest V.","family":"Pedapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan E.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"72935_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10090629","author":"S Luu","year":"2020","unstructured":"Luu, S. et al. Response to placebo in Fragile X syndrome clinical trials: an initial analysis. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci10090629 (2020).","journal-title":"Brain Sci."},{"key":"72935_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","volume":"9","author":"CA Erickson","year":"2017","unstructured":"Erickson, C. A. et al. Fragile X targeted pharmacotherapy: lessons learned and future directions. J. Neurodev Disord. 9, 7. https:\/\/doi.org\/10.1186\/s11689-017-9186-9 (2017).","journal-title":"J. Neurodev Disord"},{"key":"72935_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171723","author":"E Berry-Kravis","year":"2023","unstructured":"Berry-Kravis, E. et al. Effects of AFQ056 on language learning in fragile X syndrome. J. Clin. Invest.https:\/\/doi.org\/10.1172\/JCI171723 (2023).","journal-title":"J. Clin. Invest."},{"key":"72935_CR4","doi-asserted-by":"publisher","first-page":"16970","DOI":"10.1038\/s41598-018-34978-4","volume":"8","author":"R Hagerman","year":"2018","unstructured":"Hagerman, R. et al. Mavoglurant in Fragile X syndrome: results of two open-label, extension trials in adults and adolescents. Sci. Rep. 8, 16970. https:\/\/doi.org\/10.1038\/s41598-018-34978-4 (2018).","journal-title":"Sci. Rep."},{"key":"72935_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41398-022-01796-2","volume":"12","author":"A Kenny","year":"2022","unstructured":"Kenny, A., Wright, D. & Stanfield, A. C. EEG as a translational biomarker and outcome measure in fragile X syndrome. Transl Psychiatry. 12, 34. https:\/\/doi.org\/10.1038\/s41398-022-01796-2 (2022).","journal-title":"Transl Psychiatry"},{"key":"72935_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fnint.2019.00060","volume":"13","author":"LE Ethridge","year":"2019","unstructured":"Ethridge, L. E. et al. Auditory EEG biomarkers in Fragile X syndrome: clinical relevance. Front. Integr. Neurosci. 13, 60. https:\/\/doi.org\/10.3389\/fnint.2019.00060 (2019).","journal-title":"Front. Integr. Neurosci."},{"key":"72935_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13229-017-0140-1","volume":"8","author":"LE Ethridge","year":"2017","unstructured":"Ethridge, L. E. et al. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Mol. Autism. 8, 22. https:\/\/doi.org\/10.1186\/s13229-017-0140-1 (2017).","journal-title":"Mol. Autism"},{"key":"72935_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s11689-022-09455-9","volume":"14","author":"CR Jonak","year":"2022","unstructured":"Jonak, C. R. et al. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. J. Neurodev Disord. 14, 52. https:\/\/doi.org\/10.1186\/s11689-022-09455-9 (2022).","journal-title":"J. Neurodev Disord"},{"key":"72935_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s42003-022-03395-9","volume":"5","author":"EV Pedapati","year":"2022","unstructured":"Pedapati, E. V. et al. Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome. Commun. Biol. 5, 442. https:\/\/doi.org\/10.1038\/s42003-022-03395-9 (2022).","journal-title":"Commun. Biol."},{"key":"72935_CR10","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1021\/acschemneuro.2c00574","volume":"13","author":"TS Saraf","year":"2022","unstructured":"Saraf, T. S. et al. A 2-aminotetralin, is a potent serotonin 5-HT(1A), 5-HT(1B), and 5-HT(1D) receptor agonist that modulates cortical electroencephalogram activity in adult Fmr1 knockout mice. ACS Chem. Neurosci. 13, 3629\u20133640. https:\/\/doi.org\/10.1021\/acschemneuro.2c00574 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"72935_CR11","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0380-16.2017","author":"D Sinclair","year":"2017","unstructured":"Sinclair, D. et al. GABA-B agonist baclofen normalizes auditory-evoked neural oscillations and behavioral deficits in the Fmr1 knockout mouse model of fragile X syndrome. eNeuro. https:\/\/doi.org\/10.1523\/ENEURO.0380-16.2017 (2017).","journal-title":"eNeuro"},{"key":"72935_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s11689-017-9191-z","volume":"9","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome. J. Neurodev Disord. 9, 11. https:\/\/doi.org\/10.1186\/s11689-017-9191-z (2017).","journal-title":"J. Neurodev Disord"},{"key":"72935_CR13","doi-asserted-by":"publisher","first-page":"104794","DOI":"10.1016\/j.nbd.2020.104794","volume":"138","author":"CR Jonak","year":"2020","unstructured":"Jonak, C. R., Lovelace, J. W., Ethell, I. M., Razak, K. A. & Binder, D. K. Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X syndrome. Neurobiol. Dis. 138, 104794. https:\/\/doi.org\/10.1016\/j.nbd.2020.104794 (2020).","journal-title":"Neurobiol. Dis."},{"key":"72935_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nbd.2018.03.012","volume":"115","author":"JW Lovelace","year":"2018","unstructured":"Lovelace, J. W., Ethell, I. M., Binder, D. K. & Razak, K. A. Translation-relevant EEG phenotypes in a mouse model of Fragile X syndrome. Neurobiol. Dis. 115, 39\u201348. https:\/\/doi.org\/10.1016\/j.nbd.2018.03.012 (2018).","journal-title":"Neurobiol. Dis."},{"key":"72935_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s13311-021-01005-w","volume":"18","author":"CR Jonak","year":"2021","unstructured":"Jonak, C. R. et al. The PDE10A inhibitor TAK-063 reverses sound-evoked EEG abnormalities in a mouse model of fragile X syndrome. Neurotherapeutics. 18, 1175\u20131187. https:\/\/doi.org\/10.1007\/s13311-021-01005-w (2021).","journal-title":"Neurotherapeutics"},{"key":"72935_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s11689-021-09394-x","volume":"13","author":"PS Pirbhoy","year":"2021","unstructured":"Pirbhoy, P. S. et al. Increased 2-arachidonoyl-sn-glycerol levels normalize cortical responses to sound and improve behaviors in Fmr1 KO mice. J. Neurodev Disord. 13, 47. https:\/\/doi.org\/10.1186\/s11689-021-09394-x (2021).","journal-title":"J. Neurodev Disord"},{"key":"72935_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/cercor\/bhz141","volume":"30","author":"JW Lovelace","year":"2020","unstructured":"Lovelace, J. W. et al. Deletion of Fmr1 from forebrain excitatory neurons triggers abnormal cellular, EEG, and behavioral phenotypes in the auditory cortex of a mouse model of fragile X syndrome. Cereb. Cortex. 30, 969\u2013988. https:\/\/doi.org\/10.1093\/cercor\/bhz141 (2020).","journal-title":"Cereb. Cortex"},{"key":"72935_CR18","doi-asserted-by":"publisher","first-page":"105577","DOI":"10.1016\/j.nbd.2021.105577","volume":"162","author":"M Rais","year":"2022","unstructured":"Rais, M. et al. Functional consequences of postnatal interventions in a mouse model of Fragile X syndrome. Neurobiol. Dis. 162, 105577. https:\/\/doi.org\/10.1016\/j.nbd.2021.105577 (2022).","journal-title":"Neurobiol. Dis."},{"key":"72935_CR19","doi-asserted-by":"publisher","first-page":"105767","DOI":"10.1016\/j.nbd.2022.105767","volume":"170","author":"AJ Holley","year":"2022","unstructured":"Holley, A. J. et al. A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons. Neurobiol. Dis. 170, 105767. https:\/\/doi.org\/10.1016\/j.nbd.2022.105767 (2022).","journal-title":"Neurobiol. Dis."},{"key":"72935_CR20","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1111\/ejn.15808","volume":"56","author":"R Kat","year":"2022","unstructured":"Kat, R. & Kas, M. J. H. Largely unaffected auditory and visual sensory processing phenotypes in the evoked potentials of Fmr1 KO2 mice. Eur. J. Neurosci. 56, 5260\u20135273. https:\/\/doi.org\/10.1111\/ejn.15808 (2022).","journal-title":"Eur. J. Neurosci."},{"key":"72935_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","volume":"14","author":"E Berry-Kravis","year":"2022","unstructured":"Berry-Kravis, E. et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J. Neurodev Disord. 14, 56. https:\/\/doi.org\/10.1186\/s11689-022-09466-6 (2022).","journal-title":"J. Neurodev Disord"},{"key":"72935_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","volume":"11","author":"H Heussler","year":"2019","unstructured":"Heussler, H. et al. A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J. Neurodev Disord. 11, 16. https:\/\/doi.org\/10.1186\/s11689-019-9277-x (2019).","journal-title":"J. Neurodev Disord"},{"key":"72935_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","volume":"27","author":"EM Berry-Kravis","year":"2021","unstructured":"Berry-Kravis, E. M. et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat. Med. 27, 862\u2013870. https:\/\/doi.org\/10.1038\/s41591-021-01321-w (2021).","journal-title":"Nat. Med."},{"key":"72935_CR24","doi-asserted-by":"crossref","unstructured":"Hosmer, D. W. & Lemeshow, S. Applied Logistic Regression 2nd edn 160\u2013164 (Wiley, 2000).","DOI":"10.1002\/0471722146"},{"key":"72935_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","volume":"75","author":"FS Nahm","year":"2022","unstructured":"Nahm, F. S. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J. Anesthesiol. 75, 25\u201336. https:\/\/doi.org\/10.4097\/kja.21209 (2022).","journal-title":"Korean J. Anesthesiol"},{"key":"72935_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpsychires.2021.03.057","volume":"138","author":"EG Smith","year":"2021","unstructured":"Smith, E. G. et al. Sex differences in resting EEG power in Fragile X syndrome. J. Psychiatr Res. 138, 89\u201395. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.03.057 (2021).","journal-title":"J. Psychiatr Res."},{"key":"72935_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fnint.2019.00045","volume":"13","author":"JB Ewen","year":"2019","unstructured":"Ewen, J. B., Sweeney, J. A. & Potter, W. Z. Conceptual, regulatory and strategic imperatives in the early days of EEG-based biomarker validation for neurodevelopmental disabilities. Front. Integr. Neurosci. 13, 45. https:\/\/doi.org\/10.3389\/fnint.2019.00045 (2019).","journal-title":"Front. Integr. Neurosci."},{"key":"72935_CR28","doi-asserted-by":"publisher","first-page":"18799","DOI":"10.1038\/s41598-020-75893-x","volume":"10","author":"N Kozono","year":"2020","unstructured":"Kozono, N., Okamura, A., Honda, S., Matsumoto, M. & Mihara, T. Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome. Sci. Rep. 10, 18799. https:\/\/doi.org\/10.1038\/s41598-020-75893-x (2020).","journal-title":"Sci. Rep."},{"key":"72935_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.nbd.2019.01.002","volume":"124","author":"S Goswami","year":"2019","unstructured":"Goswami, S., Cavalier, S., Sridhar, V., Huber, K. M. & Gibson, J. R. Local cortical circuit correlates of altered EEG in the mouse model of Fragile X syndrome. Neurobiol. Dis. 124, 563\u2013572. https:\/\/doi.org\/10.1016\/j.nbd.2019.01.002 (2019).","journal-title":"Neurobiol. Dis."},{"key":"72935_CR30","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1152\/jn.00421.2011","volume":"106","author":"SM Paluszkiewicz","year":"2011","unstructured":"Paluszkiewicz, S. M., Olmos-Serrano, J. L., Corbin, J. G. & Huntsman, M. M. Impaired inhibitory control of cortical synchronization in fragile X syndrome. J. Neurophysiol. 106, 2264\u20132272. https:\/\/doi.org\/10.1152\/jn.00421.2011 (2011).","journal-title":"J. Neurophysiol."},{"key":"72935_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nbd.2018.02.011","volume":"114","author":"T Arbab","year":"2018","unstructured":"Arbab, T., Battaglia, F. P., Pennartz, C. M. A. & Bosman, C. A. Abnormal hippocampal theta and gamma hypersynchrony produces network and spike timing disturbances in the Fmr1-KO mouse model of Fragile X syndrome. Neurobiol. Dis. 114, 65\u201373. https:\/\/doi.org\/10.1016\/j.nbd.2018.02.011 (2018).","journal-title":"Neurobiol. Dis."},{"key":"72935_CR32","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.bionps.2023.100070","volume":"9","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. Reliability of resting-state electrophysiology in fragile X syndrome. Biomark. Neuropsychiatry. 9, 100070. https:\/\/doi.org\/10.1016\/j.bionps.2023.100070 (2023).","journal-title":"Biomark. Neuropsychiatry"},{"key":"72935_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1352\/1944-7558-125.6.449","volume":"125","author":"L Ethridge","year":"2020","unstructured":"Ethridge, L., Thaliath, A., Kraff, J., Nijhawan, K. & Berry-Kravis, E. Development of neural response to novel sounds in fragile X syndrome: potential biomarkers. Am. J. Intellect. Dev. Disabil. 125, 449\u2013464. https:\/\/doi.org\/10.1352\/1944-7558-125.6.449 (2020).","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"72935_CR34","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1038\/s41598-022-09633-8","volume":"12","author":"AE Boggs","year":"2022","unstructured":"Boggs, A. E. et al. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X protein from dried blood spots. Sci. Rep. 12, 5617. https:\/\/doi.org\/10.1038\/s41598-022-09633-8 (2022).","journal-title":"Sci. Rep."},{"key":"72935_CR35","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1021\/acschemneuro.2c00404","volume":"13","author":"JE Norris","year":"2022","unstructured":"Norris, J. E. et al. Hemispheric utilization of alpha oscillatory dynamics as a unique biomarker of neural compensation in females with fragile X syndrome. ACS Chem. Neurosci. 13, 3389\u20133402. https:\/\/doi.org\/10.1021\/acschemneuro.2c00404 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"72935_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnint.2019.00034","volume":"13","author":"LA De Stefano","year":"2019","unstructured":"De Stefano, L. A. et al. Developmental effects on auditory neural oscillatory synchronization abnormalities in autism spectrum disorder. Front. Integr. Neurosci. 13, 34. https:\/\/doi.org\/10.3389\/fnint.2019.00034 (2019).","journal-title":"Front. Integr. Neurosci."},{"key":"72935_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.psychres.2016.11.030","volume":"247","author":"M Alegre","year":"2017","unstructured":"Alegre, M. et al. Atypical antipsychotics normalize low-gamma evoked oscillations in patients with schizophrenia. Psychiatry Res. 247, 214\u2013221. https:\/\/doi.org\/10.1016\/j.psychres.2016.11.030 (2017).","journal-title":"Psychiatry Res."},{"key":"72935_CR38","unstructured":"Sordo, M. & Zeng, Q. in Biological and Medical Data Analysis. (eds Oliveira, J.L., Maojo, V., Mart\u00edn-S\u00e1nchez, F., & Pereira, A.S.) 193\u2013201 (Springer Berlin Heidelberg)."},{"key":"72935_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/1471-2105-11-447","volume":"11","author":"Y Guo","year":"2010","unstructured":"Guo, Y., Graber, A., McBurney, R. N. & Balasubramanian, R. Sample size and statistical power considerations in high-dimensionality data settings: a comparative study of classification algorithms. BMC Bioinform. 11, 447. https:\/\/doi.org\/10.1186\/1471-2105-11-447 (2010).","journal-title":"BMC Bioinform"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72935-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72935-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72935-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T09:09:13Z","timestamp":1729156153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72935-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["72935"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-72935-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3849272\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.E.E. has received consulting fees or project funding from Ultragenyx, Tetra Therapeutics, Healx, Novartis, and Autifony Therapeutics. CAE and EVP are inventors on a patent(s) that focus on new treatment development in fragile X syndrome held by the Cincinnati Children\u2019s Research Foundation (CCRF) and licensed out at the discretion of CCRF. CAE is a current consultant to Impel, Stalicla, and Scioto Bioscience. L.S., J.E., L.D. E.A. and J.S. declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22982"}}